ALKS 2680 shows statistically significant wakefulness improvement in NT2 and IH phase 1b

Alkermes plc.

ALKS 2680 improved mean sleep latency vs placebo at all doses in NT2 (5mg: +12 min, p<0.05; 12mg: +19 min, p<0.001; 25mg: +21 min, p<0.001).
In IH cohort, mean sleep latency improved by 8 min (5mg, p<0.05), 11 min (12mg, p<0.01), and 18 min (25mg, p<0.001).
No serious AEs or discontinuations; mild transient TEAEs including pollakiuria, insomnia, dizziness at highest dose.
Phase 2 study in narcolepsy type 2 planned for second half of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.